CORPORATE OVERVIEW Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and. | May 8, 2023
09.08.2022 - - FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma continues to progress per protocol; working to resolve partial clinical hold in AML and MDS - On track to report initial Phase 1 clinical data for FHD-609 in synovial .
01.08.2022 - CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) - Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin .
CAMBRIDGE, Mass., Jan. 07, 2022 Foghorn® Therapeutics Inc. , a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies. | January 7, 2022